Stage II HR-Positive Breast Cancer: Rach's Patient Story

What happened, in summary

Rach D. was 27 when she noticed a change in her right breast during her honeymoon. At first, she was unsure whether the lump had always been there. A January physical exam became the turning point: her doctor felt 3 masses and sent her for ultrasound. The imaging visit turned into more images, her first mammogram, and then a biopsy. On January 25, Rach learned that 4 tumors were malignant. Her diagnosis was Stage II triple-positive breast cancer, meaning the cancer was driven by estrogen receptors, progesterone receptors, and HER2. Before starting treatment, Rach sought several second opinions and chose a plan that began with neoadjuvant chemotherapy. Because she and her husband hoped to have children, she completed fertility preservation first; the process created 8 frozen embryos. Chemotherapy started March 17. Her regimen was TCHP, including Herceptin, and she also began Zoladex shots to suppress ovarian hormones. She completed 6 rounds, though low blood counts sometimes delayed treatment and high blood pressure required close management. Her treatment path also included a double mastectomy with reconstruction. As of June 2026, Rach’s experience centered on self-advocacy, fertility planning, financial stress, and the strain cancer placed on relationships. She also emphasized how important it was to choose a care team she trusted.